Ricordando Dan Perez, cofondatore della FSHD Society e forza trainante nella ricerca e nella difesa della FSHD.

Tuesday, June 24th 1:00 pm ET
Join us for a special FSHD University webinar presented by Avidity Biosciences, a biotechnology company advancing RNA-based therapies for rare muscle diseases. In this session, the Dr. Nicholas Johnson will share an overview of their approach to targeting the root cause of FSHD and provide insights into their ongoing research and development efforts. The webinar will feature a presentation on the topline results from FORTITUDE, Avidity’s Phase 1/2 clinical trial evaluating the safety, tolerability, and early signs of efficacy of their lead candidate for FSHD.
Registration Link: https://us02web.zoom.us/webinar/register/WN_cf9OJF8lSDKEWmbuxA4DDw